Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Chronic Migraine in Korea

Allergan

Status: Completed

Conditions: Migraine Disorders; Headache

Treatments: Biological: botulinum toxin Type A

Study type: Observational

Funder types: Industry

Identifiers

NCT01976611

191622-139

Details and patient eligibility

About

This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of botulinum toxin Type A to treat Chronic Migraine in clinical practice.

Enrollment: 402 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients treated with botulinum toxin Type A for chronic migraine in clinical practice.

Exclusion criteria

• None.

Trial design

402 participants in 1 patient group

BOTOX®

Description:

Patients who receive botulinum toxin Type A (BOTOX®) treatment for chronic migraine as per local standard of care in clinical practice.

Treatment:

Biological: botulinum toxin Type A